GMP, ISO custom synthesis Medicinal Chemistry; FDA new API and Intermediates, HPLC 99%+, NMR, LCMS, MSDS, COA, MOA all we provided.
Teva, Novartis, Pfizer, Hikma, Glenmark, Gilead all Site Audit approved us.
www.eosmedchem.com
1.
Baricitinib, CAS#: 1187594-09-7 (free base), HPLC 99.62%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.
Name: Baricitinib
CAS#: 1187594-09-7 (free base)
Chemical Formula: C16H17N7O2S
Exact Mass: 371.11644
Molecular Weight: 371.41688
Elemental Analysis: C, 51.74; H, 4.61; N, 26.40; O, 8.62; S, 8.63
Baricitinib Phosphate , CAS#: 1187595-84-1 (free base), HPLC 99.5%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 100g in stock.
Name: Baricitinib Phosphate
CAS#: 1187595-84-1 (phosphate)
Chemical Formula: C16H20N7O6PS
Exact Mass:
Molecular Weight: 469.4128
Elemental Analysis: C, 40.94; H, 4.29; N, 20.89; O, 20.45; P, 6.60; S, 6.83
2.
Baricitinib intermediates:
Baricitinib intermediate, 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile, CAS# 1187595-85-2, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate, CAS# 1153949-11-1, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, 1-Boc-3-azetidinone, CAS# 398489-26-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, 4-(1H-Pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl-7H-pyrrolo[2,3-d]pyrimidine, CAS# 941685-27-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate,1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, CAS# 1029716-44-6, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate,4-Chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine, CAS# 941685-26-3, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, 4-Chloropyrrolo[2,3-d]pyrimidine, CAS# 3680-69-1, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, 2-(azetidin-3-ylidene)acetonitrile (hydrochloride), CAS# 1314910-43-4, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
Baricitinib intermediate, 4-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine, CAS# 1187595-88-5, HPLC 99.2%, HNMR, C13-NMR, MASS, MSDS, COA, MOA all we provided, More than 10KG in stock.
ADDITIONAL INFORMATION
Related CAS#
1187594-09-7 (Baricitinib free base)
1187595-84-1 (Baricitinib phosphate)
REFERENCES
1: Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R, Zlotogorski A. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. doi: 10.1016/j.ebiom.2015.02.015. eCollection 2015 Apr. PubMed PMID: 26137574; PubMed Central PMCID: PMC4486197.
2: Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, Wang X, Shi ZZ, Lewis DE, Wu H, Ballantyne CM. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015 Jun 4. doi: 10.1038/ijo.2015.104. [Epub ahead of print] PubMed PMID: 26041698.
3: Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27. PubMed PMID: 25431052; PubMed Central PMCID: PMC4316868.
4: Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014 Dec;54(12):1354-61. doi: 10.1002/jcph.354. PubMed PMID: 24965573.
5: Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12. Review. PubMed PMID: 24818516.
6: Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26. PubMed PMID: 24072562.
7: van Vollenhoven RF. Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol. 2013 May;25(3):391-7. doi: 10.1097/BOR.0b013e32835fd828. Review. PubMed PMID: 23492738.
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
2018. 4.18 Janpan CPHI, Attend
2018. 5.15 Israel Biomed, Attend
2018. 6. 20 China CPHI, W4E82
2018. 8. 28 Korea CPHI, Attend
2018. 10. 9 Spain World CPHI, Attend
郵箱: info@eosmedchem.com ; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
